Evidence map›Paper›PMID 37728611›Full record

ArticleThe Journal of international medical research2023

Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study.

Randa Farah, Hussam Al-Hawari, Asma Albtoush, Amani Nofal, Tala Basheer Hyasat, Raghed Abdel Hay Abu Jabeh, Lojayn Tareq Suboh, Ahmad A Toubasi, Tareq Fatah Eqrai, Mohammad Abufaraj

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Randa FarahNephrology Division, Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan.ORCID 0000-0003-1638-9017
Hussam Al-HawariEndocrinology Division, Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan.
Asma AlbtoushPulmonary Division, Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan.
Amani NofalSchool of Medicine, University of Jordan, Amman, Jordan.ORCID 0000-0002-4011-1069
Tala Basheer HyasatSchool of Medicine, University of Jordan, Amman, Jordan.ORCID 0000-0002-5021-8054
Raghed Abdel Hay Abu JabehSchool of Medicine, University of Jordan, Amman, Jordan.ORCID 0000-0003-2291-8165
Lojayn Tareq SubohSchool of Medicine, University of Jordan, Amman, Jordan.
Ahmad A ToubasiPulmonary Division, Department of Internal Medicine, School of Medicine, University of Jordan, Amman, Jordan.ORCID 0000-0002-4688-9728
Tareq Fatah EqraiDepartment of Internal Medicine, The University of Jordan, Amman, Jordan.
Mohammad AbufarajDepartment of Special Surgery, School of Medicine, University of Jordan, Amman, Jordan.
University of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe clinical course of coronavirus disease 2019 (COVID-19) infection is often aggressive, with unfavorable outcomes for those with comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to assess the prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with COVID-19 infection who had T2DM.

methodsIn this cross-sectional study, we included adult patients with T2DM who attended an endocrinology clinic and underwent testing for COVID-19 infection.

resultsAmong 1039 included patients, the mean age was 59.5 ± 11.0 years and 429 (41.3%) were men. Overall, 87.1% of patients had received COVID-19 vaccination and 32.3% had confirmed COVID-19 infection. The COVID-19-related mortality was 3.0% and rate of post-COVID-19 lung fibrosis was 19.1%. Vaccination was associated with lower COVID-19-related mortality (odds ratio [OR]: 0.03, 95% confidence interval [CI]: 0.0-0.3) and post-COVID-19 lung fibrosis risk (OR: 0.3, 95% CI: 0.1-0.9).

conclusionPatients with T2DM exhibited a high prevalence of COVID-19 infection and associated mortality. However, COVID-19 vaccines were beneficial in reducing the risks of COVID-19-related mortality and post-infection lung fibrosis in these patients. COVID-19 vaccines and boosters are recommended for patients with T2DM. Further studies involving larger study populations are necessary to validate these findings.

Indexed as

COVID-19Diabetes Mellitus, Type 2Pulmonary FibrosisAdultAgedCOVID-19 TestingCOVID-19 VaccinesCross-Sectional StudiesDisease ProgressionFemaleHumansMaleMiddle AgedPrevalenceRisk FactorsCOVID-19 VaccinesCOVID-19COVID-19 vaccineinfection controllung fibrosismortalityrisk assessmentType 2 diabetes mellitus

Identifiers

PMID37728611
PMCPMC10515529
OpenAlexW4386877595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.